Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results Through 24 Months From a Phase 1 Study (S37.005)
Harini Sarva(Cornell University), Viviane Tabar(Memorial Sloan Kettering Cancer Center), Alfonso Fasano(University of Toronto), Andrés M. Lozano(University of Toronto), Claire Henchcliffe(University of California, Irvine), Cameron Brennan(Memorial Sloan Kettering Cancer Center), Whitney Stemple, Nicole Floro(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Kenny Yu(Memorial Sloan Kettering Cancer Center), Nauman Abid, Suneil K. Kalia(University Health Network)
Cited by 0
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k